New shot aims to boost platelets in bleeding disorder
NCT ID NCT07605845
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an injectable drug called GL-2045 in 42 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if GL-2045 can safely raise platelet counts like standard IVIg therapy but with fewer side effects. Participants receive repeated doses at different levels to find the best balance of safety and effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GL-2045
What this could lead to
If successful, this could offer a new treatment option for immune thrombocytopenia that works like IVIg but may be easier to take and have fewer side effects.
What could go wrong
This is an early Phase 1 trial with only 42 participants, so safety and effectiveness are not yet proven. The drug may not work as hoped or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fortrea Clinical Research Unit Ltd
RECRUITINGLeeds, LS11 9EH, United Kingdom